Toggle Health Problems and D

1,000 IU of vitamin D provides little benefit (Kidney transplant in this case) – April 2021

Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients (CANDLE-KIT): a Multicenter, 2×2 Factorial, Open-label, Randomized Clinical Trial

Transpl Int . 2021 Apr 22. doi: 10.1111/tri.13885


Increased chance of benefit if they had done one or more of the following:
Used more vitamin D(say 4,000 IU)
Started dosing weeks before transplant (dialysis often filters out the vitamin D)
Started with a loading dose
Used a different form of Vitamin D (such as Calcitriol)
Used a source of vitamin D that does not require a healthy gut (topical, UVB, injection)
Also added supplements which reduce inflammation (such as Omega-3)

Kidney category starts with:

Kidney category listing has 220 items

see also Overview Kidney and vitamin D
Peritoneal dialysis in titles in VitaminDWiki (3 titles as of Oct 2021)
CKD or CHRONIC KIDNEY DISEASE in title of 65 pages as of Dec 2022

Calcitriol category listing has 56 items along with related searches

Overview Kidney and vitamin D contains the following summary

 Download the PDF from VitaminDWiki

Anemia and vitamin D deficiency are associated with allograft failure, and hence, are potential therapeutic targets among kidney transplant recipients (KTRs). We conducted a multicenter, two-by-two factorial, open-label, randomized clinical trial to examine the effects of anemia correction and vitamin D supplementation on 2-year change in eGFR among KTRs (CANDLE-KIT). We enrolled 153 patients with anemia and >1-year history of transplantation across 23 facilities in Japan, and randomly assigned them to either a high or low hemoglobin target (>12.5 vs. <10.5 g/dL) and to either cholecalciferol 1000 IU/day or control. This trial was terminated early based on the planned interim intention-to-treat analyses (α=0.034). Among 125 patients who completed the study, 2-year decline in eGFR was smaller in the high vs. low hemoglobin group (i.e., -1.6±4.5 vs. -4.0±6.9 mL/min/1.73 m2 ; P=0.021), but did not differ between the cholecalciferol and control groups. These findings were supported by the fully-adjusted mixed effects model evaluating the rate of eGFR decline among all 153 participants. There were no significant between-group differences in all-cause death or the renal composite outcome in either arm. In conclusion, aggressive anemia correction showed a potential to preserve allograft kidney function.

Created by admin. Last Modification: Monday September 13, 2021 20:48:35 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
16212 Kidney_compressed.pdf PDF 2021 admin 13 Sep, 2021 20:47 402.16 Kb 210